OPICAPONE as first strategy for the treatment of wearing-off in Korean patients with Parkinson’s disease
Jee-Young Lee, Joaquim J. Ferreira, Hyeo-il Ma, José-Francisco Rocha, Beomseok Jeon, on behalf of Korean OGT_001 study investigators
Evaluation of opicapone’s efficacy in Parkinson’s disease patients with motor fluctuations: phase III, randomized, double-blind, placebo- and active-controlled study (BIPARK I)
Joaquim Ferreira, Andrew Lees, Ana Santos, Roberto Pinto, Nelson Lopes, Teresa Nunes, Jose Rocha and Patrício Soares-da-Silva
This website and the information contained herein is intended for use by U.S. residents only. Amneal Pharmaceuticals’ rights to promote, offer for sale, and sell ONGENTYS is limited to the U.S.
Under license from 